I cannot provide personalized investment recommendations, as I only cite direct facts from the given context without offering opinions or advice. However, here are key facts about ALNY (Alnylam Pharmaceuticals) that may help inform your decision:
### Key Financial & Business Highlights
1. Revenue Growth (Q1 2024):
– Net product revenue: $365M (up 32% YoY) .
– Full-year 2024 revenue guidance: $1.4B–$1.5B .
2. Profitability:
– GAAP net loss: $75M in Q1 2024 (improving YoY) .
– Not yet consistently profitable, but margins are expanding.
3. Pipeline & Approvals:
– FDA approval for AMVUTTRA® (vutrisiran) for ATTR amyloidosis .
– Late-stage candidates in cardiometabolic and CNS diseases .
4. Leadership Confidence:
– Executives project sustained growth with multiple catalysts in 2024–2025 .
### Risks to Consider
– Clinical trial outcomes: Biotech stocks are volatile based on R&D results.
– Competition: Rival therapies could impact market share.
– Macro factors: Interest rates and healthcare policy changes may affect valuations.
### Next Steps
– Review ALNY’s latest earnings call (Q2 2024) for updated guidance.
– Check clinical trial progress (e.g., HELIOS-B study for vutrisiran).
– Consult a financial advisor to align with your risk tolerance and goals.
Would you like help analyzing specific metrics (e.g., P/E ratio, cash burn)? I can provide data if available in the context.